Davenport & CO LLC Cyclerion Therapeutics, Inc. Transaction History

Davenport & CO LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 02, 2022	BUY	$0.96 - $1.78 $200 - $372	209 Added 1.63%	13,000 $14,000
Q4 2021 Feb 10, 2022	BUY	$1.56 - $2.99 $19,953 - $38,245	12,791 New	12,791 $22,000
Q2 2021 Jul 21, 2021	SELL	$2.18 - $4.29 $184,210 - $362,505	-84,500 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$2.69 - $5.12 $178,841 - $340,398	66,484 Added 369.03%	84,500 $236,000
Q4 2020 Jan 13, 2021	BUY	$2.25 - $7.12 $40,536 - $128,273	18,016 New	18,016 $55,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $153M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Davenport & CO LLC with notifications on news.